Rohto Pharmaceutical Co.,Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales of JPY 218,000 million, operating income of JPY 28,000 million, profit attributable to owners of parent of JPY 19,500 million and net income per share of JPY 170.95.